EdgarLookup

QUALYS, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that QUALYS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
209.2%
Profit Margin
Net income ÷ revenue
18.1%
Return on Assets
Net income ÷ assets
0.95x
Debt-to-Equity
Total liabilities ÷ equity
+1.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2020 Dec 31, 2020 $94.80M Feb 22, 2021
FY2020 Sep 30, 2020 $93.07M Feb 22, 2021
FY2020 Jun 30, 2020 $88.83M Feb 22, 2021
FY2020 Mar 31, 2020 $86.26M Feb 22, 2021
FY2020 Dec 31, 2019 $84.66M Feb 22, 2021
FY2020 Sep 30, 2019 $82.67M Feb 22, 2021
FY2020 Jun 30, 2019 $78.93M Feb 22, 2021
FY2020 Mar 31, 2019 $75.34M Feb 22, 2021
FY2019 Dec 31, 2018 $74.20M Feb 21, 2020
FY2019 Sep 30, 2018 $71.66M Feb 21, 2020

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $669.13M Feb 20, 2026
FY2025 Dec 31, 2024 $607.57M Feb 20, 2026
FY2025 Dec 31, 2023 $554.46M Feb 20, 2026
FY2024 Dec 31, 2022 $489.72M Feb 21, 2025
FY2023 Dec 31, 2021 $411.17M Feb 22, 2024
FY2022 Dec 31, 2020 $362.96M Feb 23, 2023
FY2021 Dec 31, 2019 $321.61M Feb 22, 2022
FY2018 Dec 31, 2018 $74.20M Feb 27, 2019
FY2018 Dec 31, 2017 $62.92M Feb 27, 2019

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $554.36M Feb 20, 2026
FY2025 Dec 31, 2024 $496.09M Feb 20, 2026
FY2025 Dec 31, 2023 $446.97M Feb 20, 2026
FY2024 Dec 31, 2022 $386.94M Feb 21, 2025
FY2023 Dec 31, 2021 $321.73M Feb 22, 2024
FY2022 Dec 31, 2020 $283.74M Feb 23, 2023
FY2021 Dec 31, 2019 $252.09M Feb 22, 2022
FY2020 Dec 31, 2018 $212.70M Feb 22, 2021
FY2019 Dec 31, 2017 $179.25M Feb 21, 2020
FY2016 Dec 31, 2016 $40.55M Feb 24, 2017

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $198.32M Feb 20, 2026
FY2025 Dec 31, 2024 $173.68M Feb 20, 2026
FY2025 Dec 31, 2023 $151.60M Feb 20, 2026
FY2024 Dec 31, 2022 $107.99M Feb 21, 2025
FY2023 Dec 31, 2021 $70.96M Feb 22, 2024
FY2020 Dec 31, 2020 $23.82M Feb 22, 2021
FY2020 Sep 30, 2020 $22.74M Feb 22, 2021
FY2020 Jun 30, 2020 $26.32M Feb 22, 2021
FY2020 Mar 31, 2020 $18.69M Feb 22, 2021
FY2020 Dec 31, 2019 $20.66M Feb 22, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $221.95M Feb 20, 2026
FY2025 Dec 31, 2024 $187.20M Feb 20, 2026
FY2025 Dec 31, 2023 $163.07M Feb 20, 2026
FY2024 Dec 31, 2022 $130.55M Feb 21, 2025
FY2023 Dec 31, 2021 $87.68M Feb 22, 2024
FY2020 Dec 31, 2020 $24.41M Feb 22, 2021
FY2020 Sep 30, 2020 $26.30M Feb 22, 2021
FY2020 Jun 30, 2020 $25.51M Feb 22, 2021
FY2020 Mar 31, 2020 $20.43M Feb 22, 2021
FY2020 Dec 31, 2019 $19.55M Feb 22, 2021

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $117.28M Feb 20, 2026
FY2025 Dec 31, 2024 $111.85M Feb 20, 2026
FY2025 Dec 31, 2023 $110.47M Feb 20, 2026
FY2024 Dec 31, 2022 $101.19M Feb 21, 2025
FY2023 Dec 31, 2021 $81.29M Feb 22, 2024
FY2022 Dec 31, 2020 $72.55M Feb 23, 2023
FY2021 Dec 31, 2019 $68.24M Feb 22, 2022
FY2020 Dec 31, 2018 $53.26M Feb 22, 2021
FY2019 Dec 31, 2017 $42.82M Feb 21, 2020
FY2016 Dec 31, 2016 $8.89M Feb 24, 2017

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $309.40M Feb 20, 2026
FY2025 Dec 31, 2024 $244.09M Feb 20, 2026
FY2025 Dec 31, 2023 $244.61M Feb 20, 2026
FY2024 Dec 31, 2022 $198.85M Feb 21, 2025
FY2023 Dec 31, 2021 $200.62M Feb 22, 2024
FY2022 Dec 31, 2020 $180.09M Feb 23, 2023
FY2021 Dec 31, 2019 $160.61M Feb 22, 2022
FY2020 Dec 31, 2018 $125.46M Feb 22, 2021
FY2019 Dec 31, 2017 $107.65M Feb 21, 2020
FY2018 Dec 31, 2016 $69.31M Feb 27, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.99M Feb 20, 2026
FY2025 Dec 31, 2024 $12.33M Feb 20, 2026
FY2025 Dec 31, 2023 $8.79M Feb 20, 2026
FY2024 Dec 31, 2022 $15.36M Feb 21, 2025
FY2023 Dec 31, 2021 $24.42M Feb 22, 2024
FY2022 Dec 31, 2020 $30.04M Feb 23, 2023
FY2021 Dec 31, 2019 $27.57M Feb 22, 2022
FY2020 Dec 31, 2018 $22.78M Feb 22, 2021
FY2019 Dec 31, 2017 $37.82M Feb 21, 2020
FY2018 Dec 31, 2016 $23.25M Feb 27, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.10B Feb 20, 2026
FY2025 Dec 31, 2024 $973.54M Feb 20, 2026
FY2024 Dec 31, 2023 $812.62M Feb 21, 2025
FY2023 Dec 31, 2022 $700.94M Feb 22, 2024
FY2022 Dec 31, 2021 $814.56M Feb 23, 2023
FY2021 Dec 31, 2020 $736.82M Feb 22, 2022
FY2020 Dec 31, 2019 $675.61M Feb 22, 2021
FY2019 Dec 31, 2018 $585.68M Feb 21, 2020
FY2018 Dec 31, 2017 $537.53M Feb 27, 2019
FY2017 Dec 31, 2016 $407.00M Feb 23, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $533.93M Feb 20, 2026
FY2025 Dec 31, 2024 $496.42M Feb 20, 2026
FY2024 Dec 31, 2023 $444.44M Feb 21, 2025
FY2023 Dec 31, 2022 $411.81M Feb 22, 2024
FY2022 Dec 31, 2021 $377.85M Feb 23, 2023
FY2021 Dec 31, 2020 $332.34M Feb 22, 2022
FY2020 Dec 31, 2019 $288.81M Feb 22, 2021
FY2019 Dec 31, 2018 $227.69M Feb 21, 2020
FY2018 Dec 31, 2017 $193.98M Feb 27, 2019
FY2017 Dec 31, 2016 $148.59M Feb 23, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $561.15M Feb 20, 2026
FY2025 Dec 31, 2024 $477.12M Feb 20, 2026
FY2025 Dec 31, 2023 $368.17M Feb 20, 2026
FY2025 Dec 31, 2022 $289.13M Feb 20, 2026
FY2024 Dec 31, 2021 $436.71M Feb 21, 2025
FY2023 Dec 31, 2020 $404.48M Feb 22, 2024
FY2022 Dec 31, 2019 $386.80M Feb 23, 2023
FY2021 Dec 31, 2018 $357.99M Feb 22, 2022
FY2020 Dec 31, 2017 $343.54M Feb 22, 2021
FY2019 Dec 31, 2016 $258.41M Feb 21, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $7.45M Feb 20, 2026
FY2025 Dec 31, 2024 $7.45M Feb 20, 2026
FY2024 Dec 31, 2023 $7.45M Feb 21, 2025
FY2023 Dec 31, 2022 $7.45M Feb 22, 2024
FY2022 Dec 31, 2021 $7.45M Feb 23, 2023
FY2021 Dec 31, 2020 $7.45M Feb 22, 2022
FY2020 Dec 31, 2019 $7.45M Feb 22, 2021
FY2020 Dec 31, 2018 $7.23M Feb 22, 2021
FY2019 Dec 31, 2017 $1.5K Feb 21, 2020
FY2017 Dec 31, 2016 $317.0K Feb 23, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($166.66M) Feb 20, 2026
FY2025 Dec 31, 2024 ($189.22M) Feb 20, 2026
FY2024 Dec 31, 2023 ($228.08M) Feb 21, 2025
FY2023 Dec 31, 2022 ($221.45M) Feb 22, 2024
FY2022 Dec 31, 2021 ($41.66M) Feb 23, 2023
FY2021 Dec 31, 2020 $3.57M Feb 22, 2022
FY2020 Dec 31, 2019 $23.19M Feb 22, 2021
FY2019 Dec 31, 2018 $27.96M Feb 21, 2020
FY2018 Dec 31, 2017 $39.92M Feb 27, 2019
FY2017 Dec 31, 2016 ($8.26M) Feb 23, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $250.26M Feb 20, 2026
FY2025 Dec 31, 2024 $232.18M Feb 20, 2026
FY2024 Dec 31, 2023 $203.67M Feb 21, 2025
FY2023 Dec 31, 2022 $173.72M Feb 22, 2024
FY2022 Dec 31, 2021 $137.33M Feb 23, 2023
FY2021 Dec 31, 2020 $74.13M Feb 22, 2022
FY2020 Dec 31, 2019 $87.56M Feb 22, 2021
FY2019 Dec 31, 2018 $41.03M Feb 21, 2020
FY2018 Dec 31, 2017 $86.59M Feb 27, 2019
FY2017 Dec 31, 2016 $86.74M Feb 23, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 5 Feb 20, 2026
FY2025 Dec 31, 2024 4 Feb 20, 2026
FY2025 Dec 31, 2023 4 Feb 20, 2026
FY2024 Dec 31, 2022 2 Feb 21, 2025
FY2023 Dec 31, 2021 1 Feb 22, 2024
FY2020 Dec 31, 2020 0 Feb 22, 2021
FY2020 Sep 30, 2020 0 Feb 22, 2021
FY2020 Jun 30, 2020 0 Feb 22, 2021
FY2020 Mar 31, 2020 0 Feb 22, 2021
FY2020 Dec 31, 2019 0 Feb 22, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 5 Feb 20, 2026
FY2025 Dec 31, 2024 4 Feb 20, 2026
FY2025 Dec 31, 2023 4 Feb 20, 2026
FY2024 Dec 31, 2022 2 Feb 21, 2025
FY2023 Dec 31, 2021 1 Feb 22, 2024
FY2020 Dec 31, 2020 0 Feb 22, 2021
FY2020 Sep 30, 2020 0 Feb 22, 2021
FY2020 Jun 30, 2020 0 Feb 22, 2021
FY2020 Mar 31, 2020 0 Feb 22, 2021
FY2020 Dec 31, 2019 0 Feb 22, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 35.73M Feb 20, 2026
FY2025 Dec 31, 2024 36.50M Feb 20, 2026
FY2024 Dec 31, 2023 36.91M Feb 21, 2025
FY2023 Dec 31, 2022 37.36M Feb 22, 2024
FY2022 Dec 31, 2021 39.11M Feb 23, 2023
FY2021 Dec 31, 2020 39.25M Feb 22, 2022
FY2020 Dec 31, 2019 39.15M Feb 22, 2021
FY2019 Dec 31, 2018 38.60M Feb 21, 2020
FY2018 Sep 30, 2018 39.02M Feb 27, 2019
FY2018 Dec 31, 2017 38.60M Feb 27, 2019